Lung cancer statistics, 2023.

Autor: Kratzer TB; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA., Bandi P; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA., Freedman ND; Tobacco Control Research Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland, USA., Smith RA; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA., Travis WD; Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York City, New York, USA., Jemal A; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA., Siegel RL; Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia, USA.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2024 Apr 15; Vol. 130 (8), pp. 1330-1348. Date of Electronic Publication: 2024 Jan 27.
DOI: 10.1002/cncr.35128
Abstrakt: Despite decades of declining mortality rates, lung cancer remains the leading cause of cancer death in the United States. This article examines lung cancer incidence, stage at diagnosis, survival, and mortality using population-based data from the National Cancer Institute, the Centers for Disease Control and Prevention, and the North American Association of Central Cancer Registries. Over the past 5 years, declines in lung cancer mortality became considerably greater than declines in incidence among men (5.0% vs. 2.6% annually) and women (4.3% vs. 1.1% annually), reflecting absolute gains in 2-year relative survival of 1.4% annually. Improved outcomes likely reflect advances in treatment, increased access to care through the Patient Protection and Affordable Care Act, and earlier stage diagnosis; for example, compared with a 4.6% annual decrease for distant-stage disease incidence during 2013-2019, the rate for localized-stage disease rose by 3.6% annually. Localized disease incidence increased more steeply in states with the highest lung cancer screening prevalence (by 3%-5% annually) than in those with the lowest (by 1%-2% annually). Despite progress, disparities remain. For example, Native Americans have the highest incidence and the slowest decline (less than 1% annually among men and stagnant rates among women) of any group. In addition, mortality rates in Mississippi and Kentucky are two to three times higher than in most western states, largely because of elevated historic smoking prevalence that remains. Racial and geographic inequalities highlight longstanding opportunities for more concerted tobacco-control efforts targeted at high-risk populations, including improved access to smoking-cessation treatments and lung cancer screening, as well as state-of-the-art treatment.
(© 2024 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: